Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals (ASX:NEU)(PINK:NURPF) announced that the Company has been informed that an additional US$5.5 million in funding will be made available by the US Army for the Company's planned Phase II clinical trial of NNZ-2566 in traumatic brain injury (TBI). With the previously announced grant of US$4 million to cover direct costs of the study, this results in a total commitment of approximately US$10 million.

adidas AG Dear journalist,

MPH Ventures Corp. (OTC: MPSFF) Suite 2230 - 885 West Georgia Street, Vancouver, BC, Canada, V6C 3E8 www.mphventurescorp.com

Granville Baird GmbH Bocholt/ Hamburg, 21.07.2008. Private equity investor Granville Baird acquires a majority stake in Meier Vakuumtechnik GmbH as part of a management buy-out. Meier specializes in the development, production and sales of equipment for manufacturing photovoltaic panels. Considerable worldwide growth is expected in this market as electricity generation from solar sources will continue to expand.

Neuren Pharmaceuticals (ASX:NEU)(PINK:NURPF) announced today that Glypromate(R) and NNZ-2566 for neuroprotection in cardiopulmonary bypass and traumatic brain injury (TBI) have been selected as one of the Top 10 most promising neuroscience projects available for partnering by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.

Neuren Pharmaceuticals Limited (ASX: NEU) - Further Validation of NNZ-2566 as a Traumatic Brain Injury Treatment - Mr David Clarke, CEO; Boardroomradio is pleased to announce that Neuren Pharmaceuticals Limited (ASX: NEU) has published an audio file.